{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:06:01Z","timestamp":1785240361268,"version":"3.55.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clml.2026.04.021","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:30:25Z","timestamp":1778085025000},"page":"e935-e941","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quad-Exposed\/Refractory Multiple Myeloma: Patients Previously Treated With Anti-CD38, IMiDs, Proteasome Inhibitors, and BCMA-Targeted Therapies"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5828-0872","authenticated-orcid":false,"given":"Magdalena","family":"Olszewska-Szopa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Vesole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Jurczyszyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clml.2026.04.021_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17050793","article-title":"Evolution of survival in patients with multiple myeloma over two decades: a real-world experience from a medium-level hospital","volume":"17","author":"Ortega-Vida","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clml.2026.04.021_bib0002","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-023-10787-5","article-title":"Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany","volume":"23","author":"Eisfeld","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clml.2026.04.021_bib0003","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjh.19148","article-title":"Quad-class exposed\/refractory myeloma is associated with short survival","volume":"204","author":"Piron","year":"2024","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2026.04.021_bib0004","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.70145","article-title":"Real-world treatment patterns and clinical outcomes among patients with triple-class\u2013Exposed and BCMA-exposed multiple myeloma within the United States","volume":"6","author":"Mian","year":"2025","journal-title":"EJHaem"},{"key":"10.1016\/j.clml.2026.04.021_bib0005","unstructured":"Van Oekelen O, Nath K, Mouhieddine TH, et al. Multiple myeloma research foundation, Norwalk, CT; 8 Marc and Jennifer Lipschultz Precision Immunology Institute at the Icahn School of Medicine. Available from: http:\/\/ashpublications.org\/blood\/article-pdf\/141\/7\/756\/2079688\/blood_bld-2022-017848-main.pdf. Accessed October 10, 2025."},{"key":"10.1016\/j.clml.2026.04.021_bib0006","doi-asserted-by":"crossref","unstructured":"Ferreri CJ, T Hildebrandt MA, Hashmi H, et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. doi:10.1038\/s41408-023-00886-8","DOI":"10.1038\/s41408-023-00886-8"},{"issue":"16 suppl","key":"10.1016\/j.clml.2026.04.021_bib0007","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1200\/JCO.2023.41.16_suppl.8008","article-title":"Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies","volume":"41","author":"Nooka","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.clml.2026.04.021_bib0008","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1200\/JCO.2022.40.16_suppl.8013","article-title":"8013 Poster Discussion Session Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents","volume":"40","author":"Touzeau","year":"2022","journal-title":"J Clin Ocol"},{"issue":"7","key":"10.1016\/j.clml.2026.04.021_bib0009","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/bloodadvances.2023011225","article-title":"CD8 effector T cells enhance teclistamab response in BCMA-exposed and -na\u00efve multiple myeloma","volume":"8","author":"Firestone","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.04.021_bib0010","first-page":"958","article-title":"BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice","author":"Zhou","year":"2023","journal-title":"Haematologica. NLM (Medline)"},{"key":"10.1016\/j.clml.2026.04.021_bib0011","doi-asserted-by":"crossref","unstructured":"Firestone RS, Socci ND, Shekarkhand T, et al. Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma Available from: http:\/\/ashpublications.org\/blood\/article-pdf\/144\/4\/402\/2235483\/blood_bld-2023-023557-main.pdf","DOI":"10.1182\/blood.2023023557"},{"issue":"20","key":"10.1016\/j.clml.2026.04.021_bib0012","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.21.01676","article-title":"Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma","volume":"40","author":"Wang","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.021_bib0013","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-026-01474-2","article-title":"Dynamics of BCMA expression in patients with relapsed\/refractory multiple myeloma receiving BCMA-directed CAR-T therapy","author":"Rana","year":"2026","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.clml.2026.04.021_bib0014","doi-asserted-by":"crossref","first-page":"1002.e1","DOI":"10.1016\/j.jtct.2025.09.003","article-title":"Impact of gamma-secretase inhibition on outcomes following BCMA CAR-T therapy in multiple myeloma: a comparison of two phase 1 trials","volume":"31","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2026.04.021_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1433774","article-title":"Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy","author":"Fu","year":"2024","journal-title":"Front Immunol. Fronts Media SA;"},{"key":"10.1016\/j.clml.2026.04.021_bib0016","series-title":"Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma. Cells","author":"Tedder","year":"2025"},{"key":"10.1016\/j.clml.2026.04.021_bib0017","first-page":"418","article-title":"Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma. Transplantation and cellular therapy","author":"Rejeski","year":"2023","journal-title":"Elsevier B.V."},{"issue":"23","key":"10.1016\/j.clml.2026.04.021_bib0018","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.2023023616","article-title":"Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies","volume":"144","author":"Touzeau","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2026.04.021_bib0019","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2023012066","article-title":"Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma","volume":"8","author":"Reyes","year":"2024","journal-title":"Blood Adv"},{"issue":"18","key":"10.1016\/j.clml.2026.04.021_bib0020","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1182\/bloodadvances.2025016712","article-title":"Sequential BCMA CAR T-cell therapy in refractory multiple myeloma","volume":"9","author":"Richardson","year":"2025","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2026.04.021_bib0021","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jtct.2025.01.051","article-title":"A phase 1 study of PBCMA- ALLO1, a non-viral, allogeneic BCMA directed CAR-T in relapsed\/refractory multiple myeloma (RRMM): Results from optimized lymphodepletion cohort (Arm C)","volume":"31","author":"Dholaria","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.clml.2026.04.021_bib0022","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","article-title":"Lenalidomide enhances the function of CS1 chimeric antigen receptor\u2013Redirected T cells against multiple myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2026.04.021_bib0023","doi-asserted-by":"crossref","unstructured":"Zhou Y, Yu Y, Xie L, et al. Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies. 2026;75:9. doi:10.1007\/s00262-025-04247-1","DOI":"10.1007\/s00262-025-04247-1"},{"key":"10.1016\/j.clml.2026.04.021_bib0024","article-title":"Abstracts of the 21st International Myeloma Society Annual Meeting OA-01 Talquetamab (tal) + Daratumumab (dara) + pomalidomide (pom) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the phase 1b TRIMM-2 study","author":"Bahlis","year":"2024","journal-title":"Abstract OA-01, IMS"},{"key":"10.1016\/j.clml.2026.04.021_bib0025","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2023-187242","article-title":"Updated results of talquetamab, a GPRC5D\u00d7 CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma with prior exposure to T-cell redirecting therapies: results of the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Jakubowiak","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.021_bib0026","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2023-181857","article-title":"BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 study","volume":"142","author":"Bal","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2026.04.021_bib0027","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO-24-01785","article-title":"Phase I trial of MCARH109, a G protein\u2013Coupled receptor class C group 5 member D (GPRC5D)\u2013Targeted chimeric antigen receptor T-cell therapy for Multiple myeloma: an updated analysis","volume":"43","author":"Jurgens","year":"2025","journal-title":"J Clin Oncol"},{"issue":"s1","key":"10.1016\/j.clml.2026.04.021_bib0028","first-page":"236","article-title":"Cevostamab in patients with RRMM who are triple-class refractory and have received a prior BCMA-targeted ADC or CAR T-cell: initial results from the Phase I\/II CAMMA 2 study","volume":"8","author":"Kumar","year":"2024","journal-title":"Hemasphere"},{"issue":"4","key":"10.1016\/j.clml.2026.04.021_bib0029","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/jha2.572","article-title":"Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment","volume":"3","author":"Baljevic","year":"2022","journal-title":"EJHaem"},{"key":"10.1016\/j.clml.2026.04.021_bib0030","first-page":"2271","article-title":"Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed\/refractory multiple myeloma: a phase 2 prospective multi-center study category: category: 600s-hematologic malignancy review category: review category: 654","volume":"146","author":"Zhou","year":"2025","journal-title":"Multiple Myeloma: Pharmacol Ther"},{"key":"10.1016\/j.clml.2026.04.021_bib0031","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2025-2276","volume":"146","author":"Chen","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.04.021_bib0032","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-025-01314-9","article-title":"Outcomes of teclistamab in patients with relapsed\/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium","volume":"15","author":"Dima","year":"2025","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2026.04.021_bib0033","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.021_bib0034","unstructured":"Sidana S, Patel KK, Peres LC, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Available from: http:\/\/ashpublications.org\/blood\/article-pdf\/145\/1\/85\/2349639\/blood_bld-2024-025945-main.pdf"},{"issue":"1","key":"10.1016\/j.clml.2026.04.021_bib0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.clml.2026.04.021_bib0036","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood.2024026216","article-title":"Standard-of-care idecabtagene vicleucel for relapsed\/refractory multiple myeloma","volume":"146","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2026.04.021_bib0037","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"New Engl J Med"},{"issue":"6","key":"10.1016\/j.clml.2026.04.021_bib0038","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.22.00690","article-title":"Phase II, open-label study of ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor\u2013T-cell therapy, in chinese patients with relapsed\/refractory multiple myeloma (CARTIFAN-1)","volume":"41","author":"Mi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.04.021_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100103","article-title":"Belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: a real-world experience","volume":"2","author":"Hultcrantz","year":"2025","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.clml.2026.04.021_bib0040","unstructured":"Van Oekelen O, Nath K, Mouhieddine TH, et al. Multiple Myeloma Research Foundation, Norwalk, CT; 8 Marc and Jennifer Lipschultz Precision Immunology Institute at the Icahn School of Medicine. Available from: http:\/\/ashpublications.org\/blood\/article-pdf\/141\/7\/756\/2079688\/blood_bld-2022-017848-main.pdf"},{"issue":"5","key":"10.1016\/j.clml.2026.04.021_bib0041","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1016\/S2352-3026(25)00048-1","article-title":"Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial","volume":"12","author":"Xia","year":"2025","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.clml.2026.04.021_bib0042","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41408-025-01386-7","article-title":"Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study","volume":"15","author":"Al Hadidi","year":"2025","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.021_bib0043","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1182\/blood-2024-211167","article-title":"Real world evidence of outcomes of patients treated with Talquetamab in a heavily pretreated population with multiple myeloma with high exposure to prior BCMA therapies- a report from the IMWG Consortium","volume":"144","author":"Janakiram","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.04.021_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.bict.2025.100001","article-title":"Talquetamab in heavily pretreated patients with multiple myeloma, including BCMA-refractory","volume":"1","author":"Vegel","year":"2025","journal-title":"Blood Immunol Cell Ther"},{"issue":"4","key":"10.1016\/j.clml.2026.04.021_bib0045","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14041316","article-title":"Impact of prior selinexor exposure on outcomes of chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma: an exploratory analysis","volume":"14","author":"Costa","year":"2025","journal-title":"J Clin Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.021_bib0046","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2024-199542","volume":"144","author":"Richter","year":"2024","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2026.04.021_bib0047","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clml.2026.04.021_bib0048","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025032536","article-title":"Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape","author":"van de Donk","year":"2026","journal-title":"Blood J"},{"issue":"1","key":"10.1016\/j.clml.2026.04.021_bib0049","article-title":"Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2026.04.021_bib0050","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","author":"Li","year":"2023","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.021_bib0051","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2025-2292","article-title":"Optimal trispecific CAR construct simultaneously targets BCMA, GPRC5D, and CD38 to treat antigen-heterogeneous multiple myeloma","volume":"146","author":"Zhou","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.021_bib0052","article-title":"Nivolumab following CAR-T failure in multiple myeloma and non-hodgkin lymphoma: results of a phase 2 study","author":"Banerjee Fred","year":"2025","journal-title":"Blood Immunol Cell Ther"},{"issue":"11","key":"10.1016\/j.clml.2026.04.021_bib0053","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","article-title":"Mezigdomide plus Dexamethasone in relapsed and refractory multiple myeloma","volume":"389","author":"Richardson","year":"2023","journal-title":"New Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.021_bib0054","doi-asserted-by":"crossref","first-page":"7543","DOI":"10.1182\/blood-2025-7543","article-title":"Real-world efficacy and safety of mezigdomide-dexamethasone in heavily pre-treatred multiple myeloma patients: an Italian case series","volume":"146","author":"De Novellis","year":"2025","journal-title":"Blood"},{"issue":"16 suppl","key":"10.1016\/j.clml.2026.04.021_bib0055","doi-asserted-by":"crossref","first-page":"TPS8070","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8070","article-title":"TPS8070 Poster Session A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed\/refractory multiple myeloma (RRMM): SUCCESSOR-2","volume":"41","author":"Richardson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.021_bib0056","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2024-198403","article-title":"Mezigdomide (MEZI) in novel-novel combinations for relapsed or refractory multiple myeloma (RRMM): preliminary results from the CA057-003 trial","volume":"144","author":"Costa","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.021_bib0057","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1182\/blood-2024-201186","article-title":"Improving anti-BCMA CAR-T functionality with novel celmods in multiple myeloma","volume":"144","author":"Aleman","year":"2024","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2026.04.021_bib0058","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1182\/blood.2025029215","article-title":"An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden","volume":"146","author":"Meermeier","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.021_bib0059","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1182\/blood-2023-174253","article-title":"Early intervention with celmods, but not imids, prevents relapse to forimtamig driven by GPRC5D-negative myeloma cells","volume":"142","author":"Eckmann","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.04.021_bib0060","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1182\/blood-2025-5728","article-title":"Pomalidomide promotes activation induced cell death of pre-activated, memory BCMA CAR-T cells in a model of high, but not low, tumor burden multiple myeloma","volume":"146","author":"Pfeffer","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2026.04.021_bib0061","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ajh.27225","article-title":"Soluble B-cell maturation antigen in multiple myeloma","volume":"99","author":"Costa","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.04.021_bib0062","doi-asserted-by":"crossref","DOI":"10.1177\/09636897251374203","article-title":"Correlation between the expression of soluble BCMA and short-term\/long-term curative effect and survival outcomes of anti-BCMA CAR-T cell therapy in relapsed\/refractory multiple myeloma","volume":"34","author":"Fu","year":"2025","journal-title":"Cell Transplant"},{"key":"10.1016\/j.clml.2026.04.021_bib0063","article-title":"Soluble B-cell maturation antigen as a prognostic marker for progression-free survival in multiple myeloma treated with BCMA-directed therapies: a systematic review and meta-analysis","author":"Borkowski","year":"2026","journal-title":"Cancers. Multidiscipl Digital Pub Instit (MDPI)"},{"key":"10.1016\/j.clml.2026.04.021_bib0064","first-page":"543","article-title":"International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma: MULTIPLE MYELOMA, GAMMOPATHIES. Leukemia","author":"Costa","year":"2025","journal-title":"Springer Nat"},{"issue":"12","key":"10.1016\/j.clml.2026.04.021_bib0065","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14124071","article-title":"Focusing on Selinexor for holding and bridging prior to CAR-T in relapsed\/refractory multiple myeloma","volume":"14","author":"Khouri","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.clml.2026.04.021_bib0066","article-title":"Optimizing selection of bridging therapies prior to CAR-T Therapy administration for multiple myeloma: clinical pearls from an expert roundtable","author":"Ailawadhi","year":"2025","journal-title":"Clin Lymphoma, Myeloma Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2026.04.021_bib0067","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"New Engl J Med"},{"issue":"16","key":"10.1016\/j.clml.2026.04.021_bib0068","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1182\/bloodadvances.2024015732","article-title":"Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma","volume":"9","author":"Frenking","year":"2025","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.clml.2026.04.021_bib0069","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1182\/blood.2025029773","article-title":"Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy","volume":"146","author":"Dhakal","year":"2025","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2026.04.021_bib0070","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO-25-01969","article-title":"Phase II study of BCMA chimeric antigen receptor T-cell therapy in patients with newly diagnosed multiple myeloma ineligible for or not proceeding to autologous stem-cell transplantation (CAREMM-001)","volume":"44","author":"Yan","year":"2026","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2026.04.021_bib0071","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ajh.26486","article-title":"Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma","volume":"97","author":"Shi","year":"2022","journal-title":"Am J Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:58:14Z","timestamp":1785239894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":71,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2152265026001321"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.021","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quad-Exposed\/Refractory Multiple Myeloma: Patients Previously Treated With Anti-CD38, IMiDs, Proteasome Inhibitors, and BCMA-Targeted Therapies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}